Insignia Financial Ceases to Be Substantial Holder in Immutep

Immutep Ltd ( (AU:IMM) ) has shared an update.

Insignia Financial Ltd, acting on behalf of itself and its subsidiaries, has notified Immutep Ltd that it has ceased to be a substantial holder in the company as of 13 March 2026. The change follows a series of on-market share purchases and sales by Insignia’s investment entities between late September and mid-December 2024, reflecting active portfolio rebalancing that ultimately reduced its holding below the substantial shareholder threshold and may slightly alter Immutep’s institutional ownership mix without indicating any change in the company’s operations.

The transactions involved IOOF Investment Management Ltd, IOOF Investment Services Ltd and MLC Investments Ltd, which collectively executed multiple trades in Immutep shares over this period. While the activity signals a shift in one major investor’s position, it does not in itself suggest a strategic move by Immutep, but it is relevant for shareholders monitoring changes in the company’s major institutional backers and potential impacts on trading liquidity and governance dynamics.

The most recent analyst rating on (AU:IMM) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Ltd is a biotechnology company focused on immuno-oncology, developing therapies that modulate the immune system to treat cancer. The company is listed on the ASX under the code IMM and attracts institutional investors that actively trade its shares as part of their portfolio management strategies.

Average Trading Volume: 16,965,718

Technical Sentiment Signal: Sell

Current Market Cap: A$75.16M

For an in-depth examination of IMM stock, go to TipRanks’ Overview page.